✦ LIBER ✦

Effect of Therapeutic Drug Monitoring (TDM) on the Efficacy and Safety of Pre-Emptive Voriconazole in Lung Transplant Recipients

✍ Scribed by Morrissey, O.; Ivulich, S.; Garlick, J.; Snell, G.; Levvey, B.; Williams, T.; Whitford, H.; Westall, G.; Paraskeva, M.; Kotsimbos, T.; Black, M.; Schneider, H.G.

Book ID: 122439042
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 133 KB
Volume: 32
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2013.01.459

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Effect of Therapeutic Drug Monitorin

The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

✍ Park, W. B.; Kim, N.-H.; Kim, K.-H.; Lee, S. H.; Nam, W.-S.; Yoon, S. H.; Song, 📂 Article 📅 2012 🏛 University of Chicago Press 🌐 English ⚖ 259 KB

Comparison of the efficacy and cost effe

Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients

✍ Janet Kelly; Dana Hurley; Ganesh Raghu 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Cyclosporine monitoring in renal transpl

Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0

✍ Cécile Loichot; Danièle Bentue-Ferrer; Nicole Bernard; Andrée Bonardet; Roselyne 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Comparison of an Innovative Everolimus-C

Comparison of an Innovative Everolimus-Containing Quadruple Immunosuppressive Regimen Versus a Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design

✍ Gottlieb, J.; Deuse, T.; Witt, C.; Neurohr, C.; Mueller-Quernheim, J.; Sommerwer 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 159 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction

✍ M Cantarovich; H Ross; J Arizon; J Orus; L Straatman; J Howlett; E Lage; M Cresp 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

✍ H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB